MOONLAKE IMMUNOTHERAPEUTICS's ticker is and the CUSIP is 61559X104. A total of 85 filers reported holding MOONLAKE IMMUNOTHERAPEUTICS in Q2 2023. The put-call ratio across all filers is - and the average weighting 1.2%.
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 21,751,284 | $465,259,965 | 17.01% |
| Cormorant Asset Management, LP | 6,892,101 | $147,422 | 9.71% |
| HighVista Strategies LLC | 122,201 | $2,613,879 | 2.13% |
| Ally Bridge Group (NY) LLC | 72,850 | $1,558,262 | 2.04% |
| Ghost Tree Capital, LLC | 195,000 | $4,171,000 | 1.23% |
| GREAT POINT PARTNERS LLC | 278,334 | $5,953,564 | 1.17% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 105,750 | $2,261,993 | 0.93% |
| SVB FINANCIAL GROUP | 16,173 | $345,940 | 0.66% |
| Velan Capital Investment Management LP | 23,400 | $500,526 | 0.43% |
| BOULDER HILL CAPITAL MANAGEMENT LP | 14,500 | $310,155 | 0.25% |